Author:
Fainberg Hernan,Oldham Justin,Molyneaux Philip,Allen Richard,Kraven Luke,Fahy William,Porte Joanne,Braybrooke Rebecca,Saini Gauri,Karsdal Morten,Leeming Diane,Triguero Isaac,Oballa Eunice,Wells Athol,Renzoni Elisabetta,Wain Louise,Noth Imre,Maher Toby,Stewart Iain,Jenkins Gisli
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference31 articles.
1. Takeda; and lecturing fees from Intermune, Boehringer Ingelheim, and Actelion, outside of the submitted work. JMO reports an unrelated grant from Boehringer Ingelheim and received personal fees from Genentech, United Therapeutics, Gatehouse Bio and AmMax Bio unrelated to the submitted work. PLM received via his institution industry-academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche outside the submitted work. LVW received via his institution industry-academic funding from GlaxoSmithKline and holds British Lung Foundation Chair in Respiratory Research (C17-1). MAK is an employee and shareholder of Nordic Biosciences and holds patents relating to neoepitopes;Tmm Hpf;Indalo and Pliant. AW reports fees for work on scientific advisory boards for Intermune
2. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline;G Raghu;Am J Respir Crit Care Med,2015
3. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis;S D Nathan;Thorax,2016
4. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis;W M Reichmann;BMC Pulm Med,2015
5. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials;P W Noble;Lancet,2011